It’s the most transparent estimate yet from one of the big AI companies, and a long-awaited peek behind the curtain for researchers. Google has just released a technical report detailing how much ...

After a 54% year-over-year sales increase for CGRP migraine drug Vyepti in the U.S., Lundbeck has raised its peak sales projection for the therapy in the key market. The Danish company now expects the ...

Megan Cerullo is a New York-based reporter for CBS MoneyWatch covering small business, workplace, health care, consumer spending and personal finance topics. She regularly appears on CBS News 24/7 to ...

The Review of Economics and Statistics Vol. 72, No. 1, Feb., 1990 The Inappropriate use of Serial Correlation Tests in Dynamic Linear Models This is the metadata section. Skip to content viewer ...

The global push for clean, reliable energy has positioned nuclear power as a critical solution, with currently more than 70 gigawatts (GW) of new nuclear capacity under construction globally, as per ...

D-Wave Quantum stock has been extremely volatile since going public through a SPAC merger roughly three years ago. While the stock has underperformed the market over the last three years, it's ...

Gilead Sciences' TROP2-targeting drug Trodelvy is already used as a third-line treatment for PD-L1-positive triple-negative breast cancer (TNBC), but could be heading for use in previously untreated ...

A teen boy looks at an iPhone screen. Reporter YouTube is one of the most popular online platforms in the U.S. among all age groups. But not all content on the video-sharing site is appropriate for ...

Hydropower is currently the world’s largest source of renewable energy. As countries push for decarbonization and hydropower remains a critical player in the energy transition, GE Vernova Inc. (GEV) ...

Quantum computing has emerged as one of the most exciting, potentially explosive plays for growth investors, and D-Wave Quantum (NYSE: QBTS) stock has seen huge valuation gains in conjunction with the ...

Bristol-Myer Squibb has only just won FDA approval for its CAR-T Breyanzi in large B-cell lymphoma (LBCL), but is already eyeing an expansion into earlier-line therapy that could overtake rival ...